Evidence map›Paper›PMID 26629412›Full record

ReviewMeta gene2015

Methylenetetrahydrofolate reductase gene C677T polymorphism and breast cancer risk: Evidence for genetic susceptibility.

Pradeep Kumar, Upendra Yadav, Vandana Rai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Meta gene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to epilepsy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018
    Pooled it
  3. Review
  4. Influence ofOpen life sciences · 2023
    Article
  5. Lack of Association ofGenetics research · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. The association betweenOncotarget · 2017
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling.International journal of molecular sciences · 2016
    Review
  18. Environmental Chemical Assessment in Clinical Practice: Unveiling the Elephant in the Room.International journal of environmental research and public health · 2016
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pradeep KumarHuman Molecular Genetics Laboratory, Department of Biotechnology, VBS Purvanchal University, Jaunpur 222 003, UP, India.
Upendra YadavHuman Molecular Genetics Laboratory, Department of Biotechnology, VBS Purvanchal University, Jaunpur 222 003, UP, India.
Vandana RaiHuman Molecular Genetics Laboratory, Department of Biotechnology, VBS Purvanchal University, Jaunpur 222 003, UP, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are several evidences supporting the role of 5-10 methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms in breast cancer (BC). Case control association studies on breast cancer have been repeatedly performed over the last two decades, but results are inconsistent. We performed a meta-analysis to confirm the association between MTHFR C677T polymorphism and BC risk. The articles were retrieved by searching the PubMed, Google Scholar, and Springer Link databases. Crude odds ratios (OR) with 95% confidence intervals (CIs) was used to assess the strength of association between C677T polymorphism and BC. Publication bias was assessed by Egger's and Begg-Mazumdar tests. Meta-analysis was performed with Open Meta Analyst. Total 75 studies with 31,315 cases and 35, 608 controls were found suitable for the inclusion in the present meta-analysis. The results of meta-analysis suggested that there were moderate significant association between C677T polymorphism and BC risk using overall comparisons in five genetic models (T vs. C: OR = 1.08, 95% CI = 1.03-1.13, p = < 0.001; TT + CT vs. CC: OR = 1.06, 95% CI = 1.02-1.09, p = < 0.001; TT vs. CC: OR = 1.17, 95% CI = 1.06-1.28, p = 0.001; CT vs. CC OR = 1.05, 95% CI = 1.01-1.08, p = 0.005; TT vs. CT + CC: OR = 1.12, 95% CI = 1.03-1.22, p = 0.005). In conclusion, results of present meta-analysis showed modest association between MTHFR C677T polymorphism with breast cancer in total studies. However, sub-group analysis results based on ethnicity showed strong significant association between TT genotype and breast cancer (TT vs. CC; OR°=°1.26; 95% CI: 1.06-1.51; p = 0.009) in Asian population but in Caucasian population such association was not observed (TT vs. CC; OR°=°1.08; 95% CI: 0.99-1.14; p = 0.05).

Indexed as

Breast cancerFolic acidMeta-analysisMTHFRPolymorphism

Identifiers

PMID26629412
PMCPMC4634353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.